Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
HIV/AIDS Therapy
Natural resistance of HIV type 2 to zidovudine described
July 24th, 2005
Scientists describe natural resistance of human immunodeficiency virus type 2 to zidovudine in a recent issue of the journal Virology. "Zidovudine (AZT) is a reverse transcriptase (RT) inhibitor widely used to treat persons infected with HIV-1 and HIV-2. Recent data on treated patients suggest differences in the antiviral activity of AZT between HIV-1 and HIV-2. "We evaluated the antiviral activity of AZT oil HIV-2 by using multiple approaches including in vitro selection experiments, analysis of growth kinetics with AZT, and phenotypic testing. A total of five wild-type (WT) HIV-2 viruses were used in the analysis. For comparison, four...
Source: Medical Letter on the CDC & FDA (2005-07-24)
|
